DEF: FibroBiologics Seeks Reverse Split, Approves Warrant Issuances

FibroBiologics, Inc. calls a Special Meeting to approve a reverse stock split to maintain Nasdaq listing and ratify recent warrant issuances totaling over 22 million shares.

Summary

• A Special Meeting of Stockholders will be held virtually on February 20, 2026, to vote on several key proposals.
• The company proposes an amendment to its Certificate of Incorporation to effect a reverse stock split of its issued and outstanding common stock and preferred stock at a ratio not less than 1-for-5 and not greater than 1-for-30, with the exact ratio to be set at the Board's discretion.
• The primary goal of the reverse stock split is to increase the per share market price of common stock to meet Nasdaq's minimum bid price requirement of $1.00 per share and the minimum market value of listed securities (MVLS) of $35.0 million.
• Stockholders are asked to approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of up to 12,110,203 shares of common stock issuable upon the exercise of outstanding warrants from a November 18, 2025 Securities Purchase Agreement (SPA) with an exercise price of $0.3303 per share.
• Stockholders are also asked to approve, under Nasdaq Listing Rule 5635(d), the issuance of up to 4,477,614 shares of common stock issuable upon the exercise of outstanding warrants from November 24, 2025 SPAs (exercise price $0.335) and up to 313,433 shares from an Engagement Letter (exercise price $0.4188).
• Further approval is sought, under Nasdaq Listing Rule 5635(d), for the issuance of up to 5,227,275 shares of common stock issuable upon the exercise of outstanding warrants from December 14, 2025 SPAs (exercise price $0.33) and up to 365,909 shares from an Engagement Letter (exercise price $0.4125).
• These warrant issuances require stockholder approval to avoid triggering cash repayment obligations for the company.
• The Board of Directors recommends a vote FOR all proposals, including the reverse stock split and the warrant issuances.

Sentiment

Score: 2

Explanation: The company is in a challenging position, facing Nasdaq delisting threats and relying on significant dilutive capital raises to maintain liquidity. While the proposals aim to address immediate compliance and funding needs, they highlight underlying financial distress and substantial dilution for existing shareholders. The need for a reverse split is a defensive measure, not indicative of strong operational performance.

Positives

• The proposed reverse stock split aims to help the company regain compliance with Nasdaq's listing requirements, potentially preventing delisting and maintaining market access.
• Approval of the warrant issuances would allow the company to receive approximately $7.482 million in gross proceeds if all warrants are exercised, which is intended for working capital and general corporate purposes.
• The virtual meeting format enhances stockholder access and participation from any location at no cost, allowing for Q&A with the Board and management.

Negatives

• The company is currently not in compliance with Nasdaq's minimum bid price requirement ($1.00 per share) and minimum market value of listed securities ($35.0 million), indicating a challenging financial position.
• The reverse stock split may not guarantee a sustained increase in stock price or prevent eventual delisting, and its effect on market price cannot be predicted with certainty.
• The reverse stock split will reduce the total number of outstanding shares, which may lead to decreased liquidity and potentially higher transaction costs for stockholders owning odd lots (less than 100 shares).
• The full exercise of the warrants (totaling over 22 million shares) will significantly dilute the ownership interest of existing stockholders.
• Failure to approve the warrant issuances would obligate the company to repay the outstanding warrant balances in cash, which could severely impact its financial condition, limit its ability to fund operations, and adversely affect business prospects.
• The process of continuing to hold stockholder meetings to obtain the requisite approvals would cause the company to incur significant legal expenses and divert management's attention from business operations.

Risks

• The reverse stock split may not increase the price of common stock over the long-term, and the common stock may still be delisted from Nasdaq.
• Delisting from Nasdaq could significantly reduce the liquidity of common stock, decrease its trading price, increase transaction costs, harm the ability to raise capital, and result in loss of investor confidence.
• The reverse stock split may decrease the liquidity of common stock due to a reduced number of outstanding shares and potentially fewer market makers.
• Stockholders owning odd lots (less than 100 shares) after the reverse stock split may face higher transaction costs when selling their shares.
• The reverse stock split could lead to a decrease in overall market capitalization if the per share price does not increase proportionally or maintain its value.
• Failure to approve the stock issuances related to the November 18, November 24, and December SPAs would trigger cash repayment obligations, potentially exhausting available cash, forcing emergency financing on unfavorable terms, and adversely affecting financial condition and growth prospects.
• The process of repeatedly seeking stockholder approval for warrant issuances would incur significant legal expenses and divert management's attention, harming business operations.
• The exercise of outstanding warrants and subsequent sale of common stock in the open market could materially and adversely affect the market price of the common stock due to dilution.

Future Outlook

The company intends to use potential proceeds from warrant exercises for working capital and general corporate purposes as it pursues longer-term financing. The Board will determine the exact ratio and timing of the reverse stock split if approved by stockholders, based on market conditions and the company's ability to regain and maintain Nasdaq listing compliance. There is no assurance that the reverse stock split will result in a sustained increase in stock price or prevent delisting for other reasons.

Management Comments

• The Board believes that a range of Reverse Stock Split ratios provides the most flexibility to achieve the desired results.
• The Board intends to effect the Reverse Stock Split only if it believes that a decrease in the number of shares outstanding is in the best interests of the Company and our stockholders and is likely to improve the trading price of our Common Stock and improve the likelihood that we will be allowed to maintain our listing on Nasdaq.
• The Board determined that the November 18, November 24, and December Offerings, including the sale and issuance of warrants, were in the best interests of the Company in light of its cash position and liquidity needs at the time.

Industry Context

The need for a reverse stock split and multiple capital raises through warrant issuances, coupled with Nasdaq delisting threats, suggests that FibroBiologics is facing significant financial challenges. This situation is common for smaller biotechnology or development-stage companies that rely heavily on capital markets for funding and may struggle to maintain market capitalization and share price amidst R&D costs and lack of revenue. The repeated need for shareholder approval for warrant exercises indicates a reliance on these financing mechanisms to sustain operations, which can be a red flag in the broader industry context.

Comparison to Industry Standards

• The company's struggle to maintain Nasdaq's minimum bid price of $1.00 and MVLS of $35.0 million indicates performance below typical standards for publicly traded companies on major exchanges. Many peer companies in the biotechnology sector, especially those in clinical development, often face similar challenges, but the frequency and scale of recent warrant issuances suggest a more acute liquidity need.
• The reliance on warrant exercises for 'working capital and general corporate purposes' and the pursuit of 'longer term financing' is a common strategy for early-stage biotech firms, but the repeated nature and the requirement for shareholder approval due to Nasdaq rules highlight a potentially unsustainable short-term financing model compared to more established industry players with stable revenue streams or robust institutional backing.
• The significant dilution from the potential issuance of over 22 million shares from warrant exercises, relative to the 66.5 million shares outstanding, is a substantial impact on existing shareholders, which is a more aggressive dilution compared to typical capital raises by financially healthier companies.

Corporate Governance

Related Party Transactions

• Pete O'Heeron, Founder, CEO, and Chairperson, holds all 2,500 shares of Series C Preferred Stock, which carry super voting rights (13,000 votes per share). He issued an irrevocable proxy to the Board to vote these shares, ensuring the Board controls 32.8% of the total voting power.

Stakeholder Impact

• **Shareholders**: Will experience significant dilution from the exercise of warrants if approved. The reverse stock split will reduce the number of shares held but aims to increase the per-share price, potentially maintaining Nasdaq listing. However, it may also decrease liquidity and increase transaction costs for odd lots. Failure to approve warrant issuances could lead to cash repayment obligations, negatively impacting company value.
• **Management/Board**: The Board's discretion over the reverse stock split ratio and implementation, along with the irrevocable proxy from the CEO's super-voting shares, gives them significant control over these strategic decisions. Failure to secure approvals would divert management attention and incur legal costs.
• **Creditors/Investors (Warrant Holders)**: Approval of warrant issuances allows them to exercise their warrants and potentially realize gains. Non-approval would trigger cash repayment, providing them with cash instead of shares.
• **Nasdaq**: The proposals are directly aimed at regaining and maintaining compliance with Nasdaq listing rules, which is critical for the company's public trading status.

Next Steps

• Stockholders to vote on proposals at the Special Meeting on February 20, 2026.
• The Board of Directors will determine the exact ratio and timing of the reverse stock split if approved by stockholders, prior to the one-year anniversary of approval.
• The company will file a current report on Form 8-K with final voting results within four business days after the Special Meeting.
• The company will continue to seek shareholder approval every 90 days for the warrant issuances if initial approval is not obtained, incurring additional legal expenses and diverting management attention.
• The company intends to use proceeds from warrant exercises for working capital and general corporate purposes, while pursuing longer-term financing.

Key Dates

Recommendation

The company is in a distressed state, evidenced by its non-compliance with Nasdaq listing requirements (both bid price and market value) and the necessity of a reverse stock split. While the reverse split is a defensive measure to avoid delisting, it does not address the underlying business fundamentals or improve operational performance. Furthermore, the company has recently undertaken multiple dilutive capital raises through warrant issuances, which require shareholder approval to avoid significant cash repayment obligations. This indicates a precarious liquidity position and a reliance on highly dilutive financing. The substantial potential dilution from these warrants, combined with the ongoing risk of delisting and the lack of clear positive operational catalysts, makes the stock a high-risk investment with significant downside potential. A seasoned investor would likely view these actions as signs of fundamental weakness and advise divesting.

Keywords

Reverse Stock Split, Nasdaq Listing Compliance, Warrant Issuance, Stockholder Approval, Capital Raise, Dilution, SEC Filing, Corporate Governance, FBLG, FibroBiologics